Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib - PubMed (original) (raw)

Clinical Trial

. 2016 Feb 20;34(6):542-9.

doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

Donald A Berry 2, Constance T Cirrincione 2, William T Barry 2, Brandelyn N Pitcher 2, Lyndsay N Harris 2, David W Ollila 2, Ian E Krop 2, Norah Lynn Henry 2, Douglas J Weckstein 2, Carey K Anders 2, Baljit Singh 2, Katherine A Hoadley 2, Michael Iglesia 2, Maggie Chon U Cheang 2, Charles M Perou 2, Eric P Winer 2, Clifford A Hudis 2

Affiliations

Clinical Trial

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A Carey et al. J Clin Oncol. 2016.

Abstract

Purpose: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapatinib added to paclitaxel, considering tumor and microenvironment molecular features.

Patients and methods: Patients with stage II to III HER2-positive breast cancer underwent tumor biopsy followed by random assignment to paclitaxel plus trastuzumab alone (TH) or with the addition of lapatinib (THL) for 16 weeks before surgery. An investigational arm of paclitaxel plus lapatinib (TL) was closed early. The primary end point was pCR in the breast; correlative end points focused on molecular features identified by gene expression-based assays.

Results: Among 305 randomly assigned patients (THL, n = 118; TH, n = 120; TL, n = 67), the pCR rate was 56% (95% CI, 47% to 65%) with THL and 46% (95% CI, 37% to 55%) with TH (P = .13), with no effect of dual therapy in the hormone receptor-positive subset but a significant increase in pCR with dual therapy in those with hormone receptor-negative disease (P = .01). The tumors were molecularly heterogeneous by gene expression analysis using mRNA sequencing (mRNAseq). pCR rates significantly differed by intrinsic subtype (HER2 enriched, 70%; luminal A, 34%; luminal B, 36%; P < .001). In multivariable analysis treatment arm, intrinsic subtype, HER2 amplicon gene expression, p53 mutation signature, and immune cell signatures were independently associated with pCR. Post-treatment residual disease was largely luminal A (69%).

Conclusion: pCR to dual HER2-targeted therapy was not significantly higher than single HER2 targeting. Tissue analysis demonstrated a high degree of intertumoral heterogeneity with respect to both tumor genomics and tumor microenvironment that significantly affected pCR rates. These factors should be considered when interpreting and designing trials in HER2-positive disease.

Trial registration: ClinicalTrials.gov NCT00770809.

© 2015 by American Society of Clinical Oncology.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.

Fig 1.

CONSORT diagram. pCR, pathologic complete response; QC, quality control; Rx, treatment; TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.

Fig 2.

Fig 2.

Pathologic complete response (pCR) rates in breast by treatment arm, stratified by hormone receptor status. Error bars represent 95% confidence limits. TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.

Fig 3.

Fig 3.

Treatment implications of molecular heterogeneity of human epidermal growth factor receptor 2 (HER2) –positive breast cancer. (A) Intrinsic subtype overall and by hormone receptor status among study population of clinically HER2-positive tumors, demonstrating that intrinsic subtype differed between hormone receptor–negative and –positive tumors (P < .001). (B) Pathologic complete response (pCR) rates by intrinsic subtype, demonstrating significant variation by intrinsic subtype (P < .001). Uncommon subtypes not shown. HER2-E, HER2 enriched; Lum, luminal.

Fig A1.

Fig A1.

Expression of target genes HER2 (ERBB2), estrogen receptor (ESR1), and proliferation gene Ki67 (MKI67) with treatment among 55 tumors with paired pretherapy and residual disease samples, demonstrating significant decrease in human epidermal growth factor receptor 2 and proliferation gene expression, but no change in estrogen receptor expression. Normal breast gene expression is provided to illustrate baseline expression patterns.

Comment in

References

    1. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–3752. - PMC - PubMed
    1. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–119. - PMC - PubMed
    1. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol. 2012;30:2585–2592. - PubMed
    1. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366:2438–2441. - PubMed
    1. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633–640. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources